The 2024 Inflection — West Virginia’s 46% Opioid-Death Decline

Last verified: May 2026

The May 14, 2025 NCHS Release

The National Center for Health Statistics, the CDC division that publishes provisional drug-overdose mortality on a 12-month rolling basis, issued the data release on May 14, 2025 showing West Virginia opioid overdose deaths fell 46% from 2023 to 2024. The figure was the single largest year-over-year percentage decline of any U.S. state. By the 12-month period ending September 2025, the rolling decline had widened to roughly 48.55%, with the Mountain State reporting an estimated 2,042 opioid deaths against a prior 3,969 — a near-halving of opioid mortality in roughly 24 months. The 2024 rate of 38.6 per 100,000 remained highest in the nation but was down sharply from the 51–58 range that defined the 2017–2018 peak. See WV opioid crisis overview.

Naloxone Saturation — The Christiansen Push

The single most-cited driver of the 2024 inflection is aggressive naloxone (Narcan) distribution. Dr. Matthew Christiansen, the West Virginia DHHR’s former director of the Office of Drug Control Policy and a Marshall University Joan C. Edwards School of Medicine faculty member in Huntington, oversaw a roughly 300% increase in naloxone distribution across the Mountain State during the 2022–2024 period. The expansion drew on opioid-settlement dollars channelled through the West Virginia First Foundation, federal SAMHSA grants, and state harm-reduction line items. Naloxone is now widely available in pharmacies (over-the-counter since 2023 federal rescheduling), at first-responder agencies, in syringe-service programs, in libraries, and through community-distribution networks. The empirical evidence from West Virginia parallels findings from Massachusetts, Vermont, and Rhode Island that population-level naloxone availability translates into measurable mortality reduction.

MAT Expansion — Buprenorphine and Methadone

Medication-assisted treatment (MAT) capacity in West Virginia expanded significantly between 2020 and 2024. The federal 2023 elimination of the X-waiver requirement for buprenorphine prescribing dramatically increased the prescriber base in the Mountain State. Per West Virginia DHHR figures, the count of patients enrolled in opioid-treatment programs (methadone clinics) and office-based buprenorphine prescribing rose substantially across that period. WVU Medicine and Marshall Health each operate substance-use-disorder clinic networks in Morgantown, Charleston, and Huntington. See Morgantown / WVU page.

Drug-Court Capacity — The Statutory Framework

West Virginia’s drug-court system operates under W. Va. Code § 62-15 (Drug Offender Accountability Act). All 31 of the state’s 31 judicial circuits operate adult drug courts; family treatment courts and juvenile drug courts add to the network. The drug-court population grew during the 2020–2024 period as Senate Bill 76 (2017) authorized expansion and as opioid-settlement dollars funded operating capacity. Drug courts divert opioid-use-disorder defendants from incarceration into structured treatment with periodic judicial review — a model that intersects with MAT prescribing and with West Virginia First Foundation funding.

Reduced Fentanyl Supply — The Federal Picture

A separately-cited driver is the apparent reduction in illicit-fentanyl supply across 2023 and 2024, attributed by federal agencies to a mix of:

• Mexican-cartel disruption — DEA and Treasury sanctions targeting Sinaloa and Jalisco New Generation Cartel chemical-precursor and finished-fentanyl supply chains
• PRC precursor controls — the People’s Republic of China’s 2019 fentanyl-analogue scheduling and 2023 precursor-control announcements (effects debated)
• Border interdiction — record CBP fentanyl seizure totals at southwest U.S. ports of entry in FY 2023 and FY 2024
• Wastewater and drug-checking data — community drug-checking and wastewater surveillance in West Virginia and adjacent states showed declining fentanyl concentrations across mid-2024

The drug-supply driver is contested by some analysts who attribute the bulk of the inflection to demand-side interventions (naloxone, MAT, drug courts, recovery housing), but the convergence of multiple supply-side and demand-side curves through 2024 produced the steep mortality decline.

The $1 Billion+ Settlement Backbone

The financial scaffolding for the 2024 inflection is the $1 billion-plus in cumulative West Virginia opioid-settlement recoveries channeled through the West Virginia First Foundation. Settlements from McKesson, Cardinal Health, AmerisourceBergen, Johnson & Johnson, Endo, Purdue Pharma, Walmart, CVS, Walgreens, Teva, and Allergan now flow into Mountain State prevention, treatment, naloxone, recovery-housing, and workforce-development programs. The settlements were litigated and negotiated principally by then-Attorney General Patrick Morrisey (now governor since January 13, 2025), and the per-capita recovery is the largest of any state. See pill-mill history page; see Gov. Morrisey page.

The Cannabis Question — Coincidence or Contributor?

The 2024 inflection coincides with West Virginia’s now-operational medical-cannabis program. The first sale occurred November 12, 2021 at Trulieve Morgantown (Sabraton); patient enrollment passed roughly 35,000 by 2026; severe chronic pain remains the most-common qualifying condition. Peer-reviewed literature on state-level associations between medical-cannabis access and opioid-prescribing or opioid-mortality patterns produced mixed findings (early Bachhuber 2014 association results were partially walked back by subsequent updated analyses). West Virginia is too small a sample to isolate a cannabis-specific contribution from the inflection, and the correlation should not be confused with causation. But the medical-cannabis program now functions as an additional tool available to clinicians and patients pursuing opioid-sparing pain management. See cannabis-as-alternative page; see qualifying conditions page.

Cannabis Reality — The 2024 Mountain State Inflection

• 46% — West Virginia’s 2023–2024 opioid overdose death decline, largest of any U.S. state per CDC NCHS
• 48.55% — the 12-month-ending-September-2025 rolling decline
• 2,042 — estimated 12-month opioid deaths ending September 2025, against a prior 3,969
• 38.6 per 100,000 — the 2024 rate; still highest in the nation but down sharply from the 2017 peak
• +300% — the Christiansen-era naloxone distribution increase
• $1B+ — West Virginia opioid-settlement recoveries financing the response architecture